Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical Vehicle Ointment Clear all
Terminated Phase 2 Interventional

Green Tea Extract in Treating Patients With Actinic Keratosis

NCT00005097
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
Polyphenon E and Placebo
Drug
Lead sponsor
Frank Meyskens
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

NCT02864082
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%
Drug
Lead sponsor
Patagonia Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 28, 2026, 4:22 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal

NCT05688735
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Isosorbide Diester Moisturizer, Control Moisturizer
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

NCT06810050
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Fremont, California • Manhattan Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

NCT00373516
View directory record Official record
Conditions
Psoriasis
Interventions
Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Sep 28, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

NCT03154333
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
diacerein 1% ointment, A placebo ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

NCT05298033
View directory record Official record
Conditions
Vitiligo
Interventions
Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy, Sham phototherapy, Vehicle
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378
View directory record Official record
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin as a Decolonizing Agent for MRSA

NCT03304873
View directory record Official record
Conditions
MRSA
Interventions
Retapamulin, Placebo Ointment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
9 Months to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

NCT04753034
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TER-101, Vehicle
Drug
Lead sponsor
Teres Bio, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Encinitas, California • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

CP-690-550 Ointment For Chronic Plaque Psoriasis

NCT01246583
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

NCT03473184
View directory record Official record
Conditions
Healthy
Interventions
Diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

NCT01228513
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ZK245186, Placebo (vehicle without active ingredient)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Anaheim, California • Honolulu, Hawaii • Boise, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

Wound Edge Changes Following Treatment With Santyl

NCT01197898
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions
Collagenase Santyl Ointment, Placebo Comparator
Biological · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

NCT02118792
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

NCT02844777
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Placebo, 5% VDA-1102, 10% VDA-1102
Drug
Lead sponsor
Vidac Pharma
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional Results available

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

NCT01300052
View directory record Official record
Conditions
Psoriasis
Interventions
AN2728 ointment, 2%, Ointment Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Fridley, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 28, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Study of TDM-180935 in Atopic Dermatitis Patients

NCT06363461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Rolling Meadows, Illinois • Covington, Louisiana • New Brighton, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 28, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

NCT01860664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
hydrocortisone ophthalmic ointment 0.5%, placebo
Drug
Lead sponsor
Koffler Vision Group
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 28, 2026, 4:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

NCT06830863
View directory record Official record
Conditions
EGFR Inhibitor-associated Rash
Interventions
ATR04-484, Vehicle
Drug
Lead sponsor
Azitra Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Hot Springs, Arkansas • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 28, 2026, 4:22 AM EDT